Role of Intravenous Ascorbic Acid in the Management of Anemia in Hemodialysis Patients.
Anemia
ascorbic acid
end-stage renal disease
Journal
Indian journal of nephrology
ISSN: 0971-4065
Titre abrégé: Indian J Nephrol
Pays: India
ID NLM: 8914356
Informations de publication
Date de publication:
Historique:
received:
21
10
2019
revised:
06
03
2020
accepted:
23
05
2020
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
ppublish
Résumé
Patients with end-stage kidney disease (ESKD) suffer from functional iron deficiency where despite the presence of sufficient iron stores in the body, adequate iron is unavailable for heme synthesis. This study hypothesis was that in patients undergoing hemodialysis (HD), administration of intravenous (IV) ascorbic acid (AA) exerts a good effect on the management of anemia, either by increasing the mobilization of iron from tissue stores or acting as an antioxidant to overcome the inflammatory block and increase the erythropoietin sensitivity. Fifty patients with ESRD who were on regular HD were included in the study. Patients' ferritin levels ranged from 500 to 1200 ng/mL with transferrin saturation of 30% or more. However, all patients were anemic and received erythropoietin therapy. Iron therapy was discontinued in the first group, whereas it was continued in the second group that received IV AA. A significant increase in the levels of Hb was observed in the second group after 6 months despite the decrease in ferritin levels in both the groups. Transferrin saturation decreased in both groups, the decrease being more in the first group. The levels of C-reactive protein (CRP) decreased in the second group, whereas these increased in the first group. Intravenous AA as an adjuvant therapy with iron exerts a favorable and significant effect on the Hb, serum ferritin, and CRP levels in patients with ESKD having anemia. The discontinuation of iron therapy only decreases the serum ferritin levels and does not improve the Hb or CRP levels.
Identifiants
pubmed: 34376935
doi: 10.4103/ijn.IJN_356_19
pii: IJN-31-230
pmc: PMC8330662
doi:
Types de publication
Journal Article
Langues
eng
Pagination
230-234Informations de copyright
Copyright: © 2020 Indian Journal of Nephrology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Blood Purif. 2007;25(1):58-61
pubmed: 17170539
Blood. 2011 Apr 28;117(17):4425-33
pubmed: 21346250
Hemodial Int. 2005 Jan;9(1):7-22
pubmed: 16191049
Am J Kidney Dis. 2009 Feb;53(2):218-28
pubmed: 18950914
Am J Kidney Dis. 1995 Mar;25(3):433-9
pubmed: 7872321
Kidney Int. 2005 Mar;67(3):1161-70
pubmed: 15698458
Am J Kidney Dis. 2006 May;47(5 Suppl 3):S11-145
pubmed: 16678659
Nephrourol Mon. 2013 Nov 27;6(1):e13351
pubmed: 24719806
Nephrol Dial Transplant. 2000 Oct;15(10):1717-8
pubmed: 11007862
J Am Soc Nephrol. 2012 Oct;23(10):1631-4
pubmed: 22935483
Nihon Jinzo Gakkai Shi. 2004;46(8):804-9
pubmed: 15645737
Semin Nephrol. 2000 Jul;20(4):345-9
pubmed: 10928336
Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S4-8
pubmed: 17699374
Am J Kidney Dis. 2006 Apr;47(4):644-54
pubmed: 16564942
Curr Med Res Opin. 2010 Feb;26(2):473-82
pubmed: 20014980
Indian J Nephrol. 2012 May;22(3):168-73
pubmed: 23087549
Acta Haematol. 2019;142(1):44-50
pubmed: 30970355
Kidney Int. 2003 Apr;63(4):1433-42
pubmed: 12631359